BIRC5 and lung cancer: Resistance to DNA-damaging agents is also evident, with survivin implicated in resistance to Cisplatin in bladder (Krafft et al., 2019), gastric (Dong et al., 2014; Sun et al., 2014), and lung cancers (Hu et al., 2016), and Cytarabine in AML (Stroopinsky et al., 2018).